Provided by Tiger Trade Technology Pte. Ltd.

Adial Pharmaceuticals

3.03
-0.0600-1.94%
Pre-market: 3.030.00000.00%04:54 EST
Volume:57.01K
Turnover:172.34K
Market Cap:3.37M
PE:-0.13
High:3.16
Open:3.01
Low:2.86
Close:3.09
52wk High:32.50
52wk Low:2.86
Shares:1.11M
Float Shares:1.06M
Volume Ratio:0.60
T/O Rate:5.37%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-23.2225
EPS(LYR):-68.0072
ROE:-155.01%
ROA:-79.36%
PB:0.75
PE(LYR):-0.04

Loading ...

Adial Pharmaceuticals trading halted, news pending

TIPRANKS
·
Feb 06

Why Is Adial Pharmaceuticals Stock (ADIL) Down Today?

TIPRANKS
·
Feb 05

Adial Pharmaceuticals Implements Reverse Stock Split to Regain Compliance

TIPRANKS
·
Feb 05

Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04

GlobeNewswire
·
Feb 04

Adial Pharmaceuticals Inc - Announces 1-for-25 Reverse Stock Split

THOMSON REUTERS
·
Feb 04

Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement

GlobeNewswire
·
Feb 04

Adial Pharmaceuticals Announces Publication of International PCT Patent Application to Protect Core Assets and Extend IP Exclusivity to at least 2045

GlobeNewswire
·
Jan 14

Adial Pharmaceuticals Director James W. Newman Jr. Resigns

Reuters
·
Jan 07

Adial Pharmaceuticals Inc. Announces Date for Upcoming Special Stockholders Meeting

Reuters
·
Dec 24, 2025

Adial Pharmaceuticals announces $2.86M warrant inducement transaction

TIPRANKS
·
Nov 26, 2025

Adial Pharmaceuticals Announces a Warrant Inducement Transaction for Approximately $2.86 Million in Gross Proceeds

GlobeNewswire
·
Nov 26, 2025

Strategic Advancements and Collaborations Propel Adial Pharmaceuticals’ Buy Rating

TIPRANKS
·
Nov 19, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 17, 2025

Adial Pharmaceuticals reports Q3 net loss of $1.8 million

Reuters
·
Nov 14, 2025

Adial Pharmaceuticals Q3 Net Income USD -1.8 Million

THOMSON REUTERS
·
Nov 14, 2025

Adial Pharmaceuticals: Implementing FDA's Recommendations Based on Eop2 Meeting, to Advance Ad04 Toward Phase 3 Development

THOMSON REUTERS
·
Nov 14, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 14, 2025

Adial Pharmaceuticals Inc expected to post a loss of 14 cents a share - Earnings Preview

Reuters
·
Nov 07, 2025

Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show

GlobeNewswire
·
Oct 17, 2025

Strategic Advancements and Genetic Testing Propel Adial Pharmaceuticals to a Buy Rating

TIPRANKS
·
Oct 11, 2025